NASDAQ · RLYB
Healthcare · Biotechnology
$16.99
Up+$0.03 (+0.18%)
Updated Oct 10, 2026, 12:18 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RLYB
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
RLYB closed at $16.99 after 20 trading sessions, up 0.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $16.75 | $17.04 | $16.75 | $16.99 | 7.88K |
| Oct 7, 2026 | $16.91 | $17.04 | $16.80 | $16.93 | 7.46K |
| Oct 6, 2026 | $16.87 | $17.08 | $16.80 | $17.08 | 1.86K |
| Oct 5, 2026 | $16.985 | $17.12 | $16.82 | $16.90 | 4.63K |
| Oct 2, 2026 | $16.69 | $17.22 | $16.69 | $17.08 | 7.85K |
| Oct 1, 2026 | $17.1599 | $17.1599 | $16.76 | $16.76 | 7.08K |
| Sep 30, 2026 | $17.24 | $17.24 | $16.925 | $17.20 | 5.96K |
| Sep 29, 2026 | $16.90 | $17.24 | $16.61 | $17.22 | 16.69K |
| Sep 28, 2026 | $16.55 | $17.05 | $16.55 | $17.05 | 16.07K |
| Sep 25, 2026 | $16.80 | $17.07 | $16.62 | $16.62 | 7.03K |
| Sep 24, 2026 | $16.74 | $16.75 | $16.61 | $16.61 | 6.84K |
| Sep 23, 2026 | $16.66 | $16.86 | $16.61 | $16.86 | 5.34K |
| Sep 22, 2026 | $16.85 | $17.11 | $16.72 | $16.92 | 7.62K |
| Sep 21, 2026 | $17.138 | $17.138 | $16.61 | $16.93 | 7.92K |
| Sep 18, 2026 | $17.16 | $17.20 | $16.92 | $17.19 | 16.09K |
| Sep 17, 2026 | $17.18 | $17.18 | $17.13 | $17.16 | 4.3K |
| Sep 16, 2026 | $17.24 | $17.24 | $16.71 | $17.09 | 18.53K |
| Sep 15, 2026 | $16.49 | $17.22 | $16.45 | $17.22 | 22.17K |
| Sep 14, 2026 | $16.98 | $16.98 | $16.50 | $16.51 | 14.26K |
| Sep 11, 2026 | $16.75 | $16.875 | $16.70 | $16.875 | 6.63K |
The latest Smart Investors Daily articles mentioning RLYB.
Company
Market Activity
Research & News
RLYB research
Company profile and research snapshot.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 15, 2025 | Jones Trading | Hold | — |
| Apr 9, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 17, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 12, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 13, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 9, 2026
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001739410/000119312526386511/d96849d8k.htm
Finnhub · May 4, 2026
Rallybio Corp: Rallybio Corp - Candid terminates merger agreement with Rallybio on May 3, 2026 - SEC filing Rallybio Corp - entitled to $50 million parent termination fee - SEC filing Rallybio...
Benzinga · May 4, 2026
ChartMill · Mar 30, 2026
Rallybio Corp (RLYB) exemplifies a high-growth momentum stock in a strong technical uptrend, meeting key Minervini Trend Template criteria with accelerating earnings.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RLYB.
